1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clinicians. 68:7–30. 2018. View Article : Google Scholar
|
2
|
Song W, Liu MG, Zhang JB, Zhang JJ, Sun MM
and Yu QK: Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in
non-Hodgkin's lymphoma. Eur Rev Med Pharmacol Sci. 20:1093–1097.
2016.PubMed/NCBI
|
3
|
Datta S, Chatterjee S, Policegoudra RS,
Gogoi HK and Singh L: Hepatitis viruses and non-Hodgkin's lymphoma:
A review. World J Virol. 1:162–173. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sun CM and Luan CF: Overexpression of
microRNA-21 in peripheral blood mononuclear cells of patients with
B-cell non-Hodgkin's lymphoma is associated with disease stage and
treatment outcome. Eur Rev Med Pharmacol Sci. 19:3397–3402.
2015.PubMed/NCBI
|
5
|
Zhu C, Ren C, Han J, Ding Y, Du J, Dai N,
Dai J, Ma H, Hu Z, Shen H, et al: A five-microRNA panel in plasma
was identified as potential biomarker for early detection of
gastric cancer. Br J Cancer. 110:2291. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Xu L, Zhang Y, Wang H, Zhang G, Ding Y and
Zhao L: Tumor suppressor miR-1 restrains epithelial-mesenchymal
transition and metastasis of colorectal carcinoma via the MAPK and
PI3K/AKT pathway. J Transl Med. 12:2442014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lu L, Katsaros D, Risch HA, Canuto EM,
Biglia N and Yu H: MicroRNA let-7a modifies the effect of
self-renewal gene HIWI on patient survival of epithelial ovarian
cancer. Mol Carcinog. 55:357–365. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bruni R, Marcantonio C, Pulsoni A, Tataseo
P, De Angelis F, Spada E, Marcucci F, Panfilio S, Bianco P,
Riminucci M, et al: microRNA levels in paraffin-embedded indolent
B-cell non-Hodgkin lymphoma tissues from patients chronically
infected with hepatitis B or C virus. BMC Infect Dis. 5:S62014.
View Article : Google Scholar
|
9
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Lawrie CH, Soneji S, Marafioti T, Cooper
CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood
J, et al: MicroRNA expression distinguishes between germinal center
B cell-like and activated B cell-like subtypes of diffuse large B
cell lymphoma. Int J Cancer. 121:1156–1161. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Nati Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar
|
12
|
Akao Y, Nakagawa Y, Kitade Y, Kinoshita T
and Naoe T: Downregulation of microRNAs-143 and −145 in B-cell
malignancies. Cancer Sci. 98:1914–1920. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ferrajoli A, Shanafelt TD, Ivan C, Shimizu
M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, et
al: Prognostic value of miR-155 in individuals with monoclonal
B-cell lymphocytosis and patients with B chronic lymphocytic
leukemia. Blood. 122:1891–1899. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Döhner H, Stilgenbauer S, Benner A,
Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M and Lichter P:
Genomic aberrations and survival in chronic lymphocytic leukemia. N
Engl J Med. 343:1910–1916. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ota A, Tagawa H, Karnan S, Tsuzuki S,
Karpas A, Kira S, Yoshida Y and Seto M: Identification and
characterization of a Novel Gene, C13orf25, as a Target for
13q31-q32 amplification in malignant lymphoma. Cancer Res.
64:3087–3095. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Mendell JT: miRiad roles for the miR-17-92
cluster in development and disease. Cell. 133:217–222. 2008.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Tagawa H, Karube K, Tsuzuki S, Ohshima K
and Seto M: Synergistic action of the microRNA-17 polycistron and
Myc in aggressive cancer development. Cancer Sci. 98:1482–1490.
2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zheng RL, Jiang YJ and Wang X: Role of
microRNAs on therapy resistance in non-Hodgkin's lymphoma. Int J
Clin ExpMed. 7:3818–3832. 2014.
|
19
|
Zanette DL, Rivadavia F, Molfetta GA,
Barbuzano FG, Proto-Siqueira R, Silva WA Jr, Falcão RP and Zago MA:
miRNA expression profiles in chronic lymphocytic and acute
lymphocytic leukemia. Braz J Med Biol Res. 40:1435–1440. 2007.
View Article : Google Scholar : PubMed/NCBI
|
20
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ventura A Young AG, Winslow MM, Lintault
L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone
JR, et al: Targeted deletion reveals essential and overlapping
functions of the miR-17~92 Family of miRNA clusters. Cell.
132:875–886. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Jin HY, Oda H, Lai M, Skalsky RL, Bethel
K, Shepherd J, Kang SG, Liu WH, Sabouri-Ghomi M, Cullen BR, et al:
MicroRNA-17~92 plays a causative role in lymphomagenesis by
coordinating multiple oncogenic pathways. Embo J. 32:2377–2391.
2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔ C T method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
24
|
O'Donnell KA, Wentzel EA, Zeller KI, Dang
CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1
expression. Nature. 435:839–843. 2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Jin HY, Lai M and Xiao C: MicroRNA-17~92
is a powerful cancer driver and a therapeutic target. Cell Cycle.
13:495–496. 2014. View
Article : Google Scholar : PubMed/NCBI
|
26
|
Robertus JL, Harms G, Blokzijl T, Booman
M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P and van
den Berg A: Specific expression of miR-17-5p and miR-127 in
testicular and central nervous system diffuse large B-cell
lymphoma. Mod Pathol. 22:547–555. 2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Lenz G, Wright GW, Emre NC, Kohlhammer H,
Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, et al:
Molecular subtypes of diffuse large B-cell lymphoma arise by
distinct genetic pathways. Proc Nati Acad Sci USA. 105:13520–13525.
2008. View Article : Google Scholar
|
28
|
Zhao JJ, Lin J, Lwin T, Yang H, Guo J,
Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, et al:
microRNA expression profile and identification of miR-29 as a
prognostic marker and pathogenetic factor by targeting CDK6 in
mantle cell lymphoma. Blood. 115:2630–2639. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Lawrie CH, Chi J, Taylor S, Tramonti D,
Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J,
Wainscoat JS and Hatton CS: Expression of microRNAs in diffuse
large B cell lymphoma is associated with immunophenotype, survival
and transformation from follicular lymphoma. J Cell Mol Med.
13:1248–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Fassina A, Marino F, Siri M, Zambello R,
Ventura L, Fassan M, Simonato F and Cappellesso R: The miR-17-92
microRNA cluster: A novel diagnostic tool in large B-cell
malignancies. Lab Invest. 92:1574–1582. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Benetatos L and Vartholomatos G:
Deregulated microRNAs in multiple myeloma. Cancer. 118:878–887.
2012. View Article : Google Scholar : PubMed/NCBI
|
32
|
Spaccarotella E, Pellegrino E, Ferracin M,
Ferreri C, Cuccuru G, Liu C, Iqbal J, Cantarella D, Taulli R,
Provero P, et al: STAT3-mediated activation of microRNA cluster
17~92 promotes proliferation and survival of ALK-positive
anaplastic large cell lymphoma. Haematologica. 99:116–124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Schotte D, Pieters R and Boer MLD:
MicroRNAs in acute leukemia: From biological players to clinical
contributors. Leukemia. 26:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
|